Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Author index

Page Path
HOME > Browse articles > Author index
Search
Hyan-Chul Rhim 1 Article
Comparison of WHO and RECIST Criteria for Response in Metastatic Colorectal Carcinoma
Jung-Hye Choi, Myung-Ju Ahn, Hyan-Chul Rhim, Jin-Woo Kim, Gang-Hong Lee, Young-Yeul Lee, In-Soon Kim
Cancer Res Treat. 2005;37(5):290-293.   Published online October 31, 2005
DOI: https://doi.org/10.4143/crt.2005.37.5.290
AbstractAbstract PDFPubReaderePub
Purpose

This study compared the WHO criteria with the response evaluation criteria in solid tumors (RECIST) in the same patients with metastatic colorectal cancer in order to determine the significance of the RECIST. In addition, this study compared the estimations of medical oncologists with those of a radiologist.

Materials and Methods

Between 2002 and 2005, a total of 48 patients (male: female ratio, 29:19; median age, 58 years) with measurable lesions receiving chemotherapy for metastatic colorectal carcinoma were enrolled in this study. Two medical oncologists and one radiologist, who were blinded to the patients' condition, independently reviewed all the CT images. The results were compared using a kappa test.

Results

The kappa test for concordance between the WHO and RECIST criteria of the medical oncologists and the radiologist were 0.908 and 0.841, respectively. The level of concordance between the investigators using the WHO and RECIST were 0.722 and 0.753, respectively.

Conclusion

The RECIST criteria are comparable to the WHO criteria in evaluating the response of colorectal carcinoma, but have simple and reproducible guidelines. The use of RECIST is recommended for evaluating the treatment efficacy in clinical trials and practice.

Citations

Citations to this article as recorded by  
  • A nomogram prognostic model for early hepatocellular carcinoma with diabetes mellitus after primary liver resection based on the admission characteristics
    Menghan Zhang, Qi Wang, Gongming Zhang, Guangming Li, Ronghua Jin, Huichun Xing
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
  • Feasibility of an artificial intelligence system for tumor response evaluation
    Nie Xiuli, Chen Hua, Gao Peng, Yu Hairong, Sun Meili, Yan Peng
    BMC Medical Imaging.2024;[Epub]     CrossRef
  • Immunotherapy Assessment: A New Paradigm for Radiologists
    Vincenza Granata, Roberta Fusco, Sergio Venanzio Setola, Igino Simonetti, Carmine Picone, Ester Simeone, Lucia Festino, Vito Vanella, Maria Grazia Vitale, Agnese Montanino, Alessandro Morabito, Francesco Izzo, Paolo Antonio Ascierto, Antonella Petrillo
    Diagnostics.2023; 13(2): 302.     CrossRef
  • Study on the Application Value of Lung-RADS in the Differential Diagnosis of Benign and Malignant Lung Nodules
    ·马木提 依力夏提
    Advances in Clinical Medicine.2023; 13(12): 20190.     CrossRef
  • Reliability and accuracy in radiographic measurements of musculoskeletal tumors
    Alec S. Kellish, Sandra Miskiel, John Gaughan, Veniamin Barshay, Tae W. Kim, Christina J. Gutowski
    Journal of Orthopaedic Research.2022; 40(7): 1654.     CrossRef
  • Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance
    Anyue Yin, Johan G. C. van Hasselt, Henk-Jan Guchelaar, Lena E. Friberg, Dirk Jan A. R. Moes
    Scientific Reports.2022;[Epub]     CrossRef
  • Correlation Between Early Time-to-Event Outcomes and Overall Survival in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Receiving Definitive Chemoradiation Therapy: Systematic Review and Meta-Analysis
    Christopher M. Black, Sam Keeping, Ali Mojebi, Karthik Ramakrishnan, Diana Chirovsky, Navneet Upadhyay, Dylan Maciel, Dieter Ayers
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • A quantitative and comparative evaluation of stereotactic spine radiosurgery local control: proposing a consistent measurement methodology
    Ran Harel, Tehila Kaisman-Elbaz, Todd Emch, Paul Elson, Samuel T Chao, John H Suh, Lilyana Angelov
    Neurosurgical Focus.2022; 53(5): E10.     CrossRef
  • Lung-RADS Version 1.1: Challenges and a Look Ahead, From the AJR Special Series on Radiology Reporting and Data Systems
    Lydia Chelala, Rydhwana Hossain, Ella A. Kazerooni, Jared D. Christensen, Debra S. Dyer, Charles S. White
    American Journal of Roentgenology.2021; 216(6): 1411.     CrossRef
  • Perillyl alcohol as a treatment for cancer: A systematic review
    Aimée Obolari Durço, Lino Sérgio Rocha Conceição, Diego Santos de Souza, Carlos Anselmo Lima, Jullyana de Souza Siqueira Quintans, Márcio Roberto Viana dos Santos
    Phytomedicine Plus.2021; 1(3): 100090.     CrossRef
  • Neoadjuvant Chemotherapy for Advanced Gallbladder Cancer: Do We have Enough Evidence? A Systematic Review
    Shah Naveed, Hasina Qari, Cao M Thau, Pipit Burasakarn, Abdul W Mir
    Euroasian Journal of Hepato-Gastroenterology.2021; 11(2): 87.     CrossRef
  • Objective response rate assessment in oncology: Current situation and future expectations
    Nuri Faruk Aykan, Tahsin Özatlı
    World Journal of Clinical Oncology.2020; 11(2): 53.     CrossRef
  • Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma
    Omar Abdel-Rahman, Zeinab Elsayed
    Cochrane Database of Systematic Reviews.2020;[Epub]     CrossRef
  • What scans we will read: imaging instrumentation trends in clinical oncology
    Thomas Beyer, Luc Bidaut, John Dickson, Marc Kachelriess, Fabian Kiessling, Rainer Leitgeb, Jingfei Ma, Lalith Kumar Shiyam Sundar, Benjamin Theek, Osama Mawlawi
    Cancer Imaging.2020;[Epub]     CrossRef
  • Herb–drug interactions between the medicinal mushrooms Lingzhi and Yunzhi and cytotoxic anticancer drugs: a systematic review
    Chun Sing Lam, Lok Pui Cheng, Li Min Zhou, Yin Ting Cheung, Zhong Zuo
    Chinese Medicine.2020;[Epub]     CrossRef
  • Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy
    Sirisha L. Mushti, Flora Mulkey, Shenghui Tang, Harpreet Singh, Steven J. Lemery, Kirsten B. Goldberg, Rajeshwari Sridhara, Patricia Keegan, Paul G. Kluetz, Richard Pazdur, Marc R. Theoret, Julia A. Beaver
    Current Oncology Reports.2020;[Epub]     CrossRef
  • Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma
    Yoko Tomita, Max Moldovan, Rachael Chang Lee, Amy HC Hsieh, Amanda Townsend, Timothy Price
    Cochrane Database of Systematic Reviews.2020;[Epub]     CrossRef
  • The role of neoadjuvant chemotherapy or chemoradiotherapy for advanced gallbladder cancer – A systematic review
    Abdul R Hakeem, Michail Papoulas, Krishna V Menon
    European Journal of Surgical Oncology.2019; 45(2): 83.     CrossRef
  • Polymorphisms of genes encoding drug transporters or cytochrome P450 enzymes and association with clinical response in cancer patients: a systematic review
    Inthuorn Kulma, Kanyarat Boonprasert, Kesara Na-Bangchang
    Cancer Chemotherapy and Pharmacology.2019; 84(5): 959.     CrossRef
  • Identification of a 13‑gene‑based classifier as a potential biomarker to predict the effects of fluorouracil‑based chemotherapy in colorectal cancer
    Zuhuan Gan, Qiyuan Zou, Yan Lin, Zihai Xu, Zhong Huang, Zhichao Chen, Yufeng Lv
    Oncology Letters.2019;[Epub]     CrossRef
  • Tumor Response Assessment for Precision Cancer Therapy: Response Evaluation Criteria in Solid Tumors and Beyond
    Mizuki Nishino
    American Society of Clinical Oncology Educational Book.2018; (38): 1019.     CrossRef
  • Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe
    Ralf Gutzmer, Kevin J. Harrington, Christoph Hoeller, Celeste Lebbé, Josep Malvehy, Katarina Öhrling, Gerald Downey, Reinhard Dummer
    European Journal of Dermatology.2018; 28(6): 736.     CrossRef
  • Unidimensional measurement may be superior to assess primary tumor response after neoadjuvant chemotherapy for nasopharyngeal carcinoma
    Chuanben Chen, Xiurong Lin, Yuanji Xu, Penggang Bai, Youping Xiao, Yuhui Pan, Chao Li, Zhizhong Lin, Mingwei Zhang, Yunbin Chen
    Oncotarget.2017; 8(29): 46937.     CrossRef
  • Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis?
    Toru Mizuguchi, Toshihiko Torigoe, Fukino Satomi, Hiroaki Shima, Goro Kutomi, Shigenori Ota, Masayuki Ishii, Hiroshi Hayashi, Sumiyo Asakura, Yoshihiko Hirohashi, Makoto Meguro, Yasutoshi Kimura, Toshihiko Nishidate, Kenji Okita, Masaho Ishino, Atsushi Mi
    Surgery Today.2016; 46(2): 139.     CrossRef
  • Comparison of WHO, RECIST 1.1, EORTC, and PERCIST criteria in the evaluation of treatment response in malignant solid tumors
    Mustafa Aras, Tanju Y. Erdil, Faysal Dane, Serkan Gungor, Tunc Ones, Fuat Dede, Sabahat Inanir, Halil T. Turoglu
    Nuclear Medicine Communications.2016; 37(1): 9.     CrossRef
  • Recommendations for improving the quality of reporting clinical electrochemotherapy studies based on qualitative systematic review
    Luca G. Campana, A. James P. Clover, Sara Valpione, Pietro Quaglino, Julie Gehl, Christian Kunte, Marko Snoj, Maja Cemazar, Carlo R. Rossi, Damijan Miklavcic, Gregor Sersa
    Radiology and Oncology.2016; 50(1): 1.     CrossRef
  • Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review
    Jung Han Kim
    Oncotarget.2016; 7(12): 13680.     CrossRef
  • Assessment of Treatment Response Using PET
    Sandip Basu, Rakesh Kumar, Rohit Ranade
    PET Clinics.2015; 10(1): 9.     CrossRef
  • Single-Lesion Measurement per Organ for Assessing Tumor Response in Advanced Gastric Cancer
    Hyeong Su Kim, Ji Won Kim, Jung Han Kim, Dae Ro Choi, A. Rum Han, Min-Joeng Kim, Byung Chun Kim, Dae Young Zang
    Oncology.2015; 88(2): 69.     CrossRef
  • Tumor response assessment by measuring the single largest lesion per organ in patients with advanced non-small cell lung cancer
    Hyeong Su Kim, Jung Han Kim, Ik Yang
    Lung Cancer.2014; 85(3): 385.     CrossRef
  • Nucleotide excision repair gene polymorphisms and prognosis of non-small cell lung cancer patients receiving platinum-based chemotherapy: A meta-analysis based on 44 studies
    DONGNING HUANG, YANG ZHOU
    Biomedical Reports.2014; 2(4): 452.     CrossRef
  • XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis
    Fanghui Ye, Zhenfang Liu, Aihua Tan, Ming Liao, Zengnan Mo, Xiaobo Yang
    Cancer Chemotherapy and Pharmacology.2013; 71(3): 733.     CrossRef
  • Relationship between 6‐ and 9‐month progression‐free survival and overall survival in patients with metastatic urothelial cancer treated with first‐line cisplatin‐based chemotherapy
    Matthew D. Galsky, Susan Krege, Chia‐Chi Lin, Noah Hahn, Thorsten Ecke, Erin Moshier, Guru Sonpavde, James Godbold, William K. Oh, Aristotle Bamias
    Cancer.2013; 119(16): 3020.     CrossRef
  • Diagnostic and therapeutic imaging for cancer: Therapeutic considerations and future directions
    Mack Roach, Jean‐Louis Alberini, Alain Paul Pecking, Alessandro Testori, Francesco Verrecchia, Javier Soteldo, Ute Ganswindt, John L. Joyal, John W. Babich, Russell S. Witte, Evan Unger, Ronald Gottlieb
    Journal of Surgical Oncology.2011; 103(6): 587.     CrossRef
  • 17,293 View
  • 114 Download
  • 34 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP